title: The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans.
abstract: Obesity is a major public health issue worldwide. Understanding how the brain controls appetite offers promising inroads toward new therapies for obesity. Peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) are coreleased postprandially and reduce appetite and inhibit food intake when administered to humans. However, the effects of GLP-1 and the ways in which PYY and GLP-1 act together to modulate brain activity in humans are unknown. Here, we have used functional MRI to determine these effects in healthy, normal-weight human subjects and compared them to those seen physiologically following a meal. We provide a demonstration that the combined administration of PYY(3-36) and GLP-1(7-36 amide) to fasted human subjects leads to similar reductions in subsequent energy intake and brain activity, as observed physiologically following feeding.
authors: Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
authors: Akila
authors: A
authors: De Silva
authors: Victoria
authors: V
authors: Salem
authors: Christopher J
authors: CJ
authors: Long
authors: Aidan
authors: A
authors: Makwana
authors: Rexford D
authors: RD
authors: Newbould
authors: Eugenii A
authors: EA
authors: Rabiner
authors: Mohammad A
authors: MA
authors: Ghatei
authors: Stephen R
authors: SR
authors: Bloom
authors: Paul M
authors: PM
authors: Matthews
authors: John D
authors: JD
authors: Beaver
authors: Waljit S
authors: WS
authors: Dhillo
mesh_terms: D000328:Adult; D001066:Appetite / Q000187:drug effects* / Q000502:physiology; D001835:Body Weight; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D004435:Eating / Q000187:drug effects* / Q000502:physiology; D002149:Energy Intake / Q000187:drug effects* / Q000502:physiology; D005215:Fasting; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage*; D006801:Humans; D007118:Immunoassay; D007262:Infusions, Intravenous; D008279:Magnetic Resonance Imaging; D008297:Male; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology; D010446:Peptide Fragments / Q000008:administration & dosage*; D019894:Peptide YY / Q000008:administration & dosage*; D019518:Postprandial Period; D016037:Single-Blind Method
chemical_list: D010446:Peptide Fragments; D019894:Peptide YY; C055453:glucagon-like peptide 1 (7-36)amide; D052216:Glucagon-Like Peptide 1